Specific cancer antigens including carcinoembryonic antigen (CEA), are utilized clinically to monitor CRC disease progression and is one of the most promising tumor associated antigens (TAAs) (Thompson et al., 1991). The gene discussed is CEACAM5; the disease is colorectal carcinoma.